Arcellx · 7 hours ago
Principal Scientist, Translational Lead
Rockville, MD
Full-time
Onsite
Senior Level, Lead/Staff
$150K/yr - $177K/yr
8+ years expArcellx is a public, clinical-stage biotechnology company focused on innovative cell therapies for cancer and other diseases. They are seeking a Principal Scientist, Translational Lead to drive translational strategy and execution across early-stage clinical programs, integrating high-dimensional biomarker and clinical data to inform research and development efforts.
BiopharmaBiotechnologyHealth CareLife SciencePharmaceutical
Responsibilities
Drive translational strategy for early-phase clinical programs, incorporating biomarker hypotheses, patient selection, and endpoint optimization
Serve as the lead for biomarker components in clinical protocols, IND submissions, and regulatory engagements
Align translational goals with key clinical milestones and trial objectives
Design and execute analysis plans for high-dimensional datasets including flow cytometry, RNA-seq, single-cell, and spatial omics
Lead integration of molecular and clinical data to uncover pharmacodynamic signals, stratification markers, and mechanisms of resistance
Automate and analyze complex flow cytometry and CyTOF datasets using tools such as FlowJo, R (e.g., flowCore, CytoML, ggcyto), or Python-based pipelines
Apply modern statistical and machine learning methods to uncover actionable insights, ensuring analytic reproducibility and compliance
Contribute to governance meetings, internal reviews, and external scientific communications (e.g., manuscripts, abstracts)
Provide thought leadership at the interface of clinical development and translational science
Evaluate new biomarker platforms and external datasets to expand translational capabilities
Mentor junior scientists and cultivate a high-performing, collaborative translational culture
Qualification
Required
PhD in Bioinformatics, Computational Biology, Immunology, Molecular Biology, or related discipline
8+ years of industry experience in translational medicine, biomarkers, or bioinformatics in oncology, immunology, or rare disease
Proficiency in automated flow cytometry analysis, including multicolor panel data interpretation and integration with other biomarker modalities
Hands-on fluency in R and/or Python for statistical modeling, data visualization, and reproducible bioinformatics
Demonstrated ability to design and execute translational analysis plans and influence clinical development
Experience contributing to INDs or regulatory filings involving biomarker or flow cytometry data
Familiarity with early-phase trials in cell therapy, immuno-oncology, or engineered therapeutics
Experience working in GCP/GxP-regulated environments or defining analytics/compliance workflows
Exposure to tools such as FlowJo, Cytobank, Spectre, or Bioconductor-based cytometry packages
Background in small biotech or matrixed R&D settings with high execution ownership
Benefits
100% coverage for medical, dental and vision for team members and dependents
Unlimited vacation
A 3-day weekend every month
Fully-paid parental leave for up to 6 months
Tuition reimbursement
401k employer contribution
Relocation assistance for roles if required
Company
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
51-200 employees
H1B Sponsorship
Arcellx has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (12)
2024 (4)
2022 (2)
Funding
Current Stage
Public CompanyTotal Funding
$622MKey Investors
Kite Pharma
2023-11-15Post Ipo Equity· $200M
2022-12-09Post Ipo Equity· $100M
2022-06-15Post Ipo Equity· $112M
Leadership Team
Michelle Gilson
Chief Financial Officer
Brad Gliner
Vice President, Clinical Research and Regulatory Affairs
Recent News
2025-12-11
2025-12-08
Company data provided by crunchbase